Maria Bhatt

Maria Bhatt leads clinical research for anaplastic thyroid cancer, one of the most rapidly lethal malignancies. Her research contributed to establishing the activity of BRAF/MEK inhibitor combination therapy (dabrafenib plus trametinib) in BRAF V600E-mutated anaplastic thyroid cancer, which obtained FDA approval and transformed the prognosis of this historically uniformly fatal disease. She has characterized predictors of response and mechanisms of acquired resistance to BRAF/MEK-targeted therapy in anaplastic thyroid cancer. Her translational work advances combination immunotherapy and targeted therapy strategies to further improve outcomes in this aggressive malignancy.